Baidu
map

JAMA Intern Med:住院期间活动障碍评估预测老年急性心肌梗死功能预后

2019-10-14 MedSci MedSci原创

住院期间评估的活动障碍是预测老年AMI幸存者功能下降的有效手段

许多老年急性心肌梗死(AMI)幸存者会存在各方面的功能衰退,而行动障碍被认为是导致功能下降的一个风险因素,近日研究人员探讨老年AMI患者在住院期间活动障碍的发现,作为老年AMI患者功能下降的危险指标。

2587例75岁以上AMI住院患者参与研究,使用定时"向上和向下"运动评估AMI住院期间的活动性,评分分类为正常(≤15秒完成),轻度损伤 (>15到或25秒完成),中度损伤(>25秒至完成)和重度损伤(无法完成)。在基线检查和出院后6个月评估日常生活活动(ADL,如洗澡、穿衣、家中走动)和步行0.4公里自我报告功能。主要结局为1个或以上ADLS恶化,从基线到出院后6个月,丧失行走0.4公里的能力。通过多变量调整的logistic回归,评价了运动障碍与功能下降的风险之间的关联。

患者平均年龄为81.4岁,男性1462例(56.5%)。在AMI住院期间,有半数以上患者存在活动障碍,21.8%(564/2587)有轻度损害,16.0%(414/2587)有中度损害,15.2%(391/2587)有严重的活动障碍,12.8%(332/2587)出现ADL下降,16.7%(431/2587)报告0.4km活动能力下降。仅有3.8%的住院期间活动性评分分类为正常患者出现ADL下降,而轻度损伤为6.9%(aOR 1.24),中度损伤者为18.6%(77/414,aOR:2.67),重度损伤者34.7%(136/391,aOR:5.45)。11%的住院期间活动性评分分类为正常患者丧失行走0.4公里的能力,而轻度损伤者为15.2%(85/558,aOR:1.51),中度损伤为19.0%(78/411,aOR:2.03),重度损伤为24.6%(95/386,aOR:3.25)。

住院期间评估的活动障碍是预测老年AMI幸存者功能下降的有效手段。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=813235, encodeId=5015813235f8, content=号好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61664774766, createdName=www.kangshiyizs, createdTime=Tue Aug 25 23:00:14 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006908, encodeId=dda9200690809, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat May 23 05:10:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492856, encodeId=c3131492856e8, content=<a href='/topic/show?id=447732948d0' target=_blank style='color:#2F92EE;'>#功能预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32948, encryptionId=447732948d0, topicName=功能预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=728c8977388, createdName=zsyan, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610030, encodeId=8dfe161003071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2020-08-25 www.kangshiyizs

    号好用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=813235, encodeId=5015813235f8, content=号好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61664774766, createdName=www.kangshiyizs, createdTime=Tue Aug 25 23:00:14 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006908, encodeId=dda9200690809, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat May 23 05:10:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492856, encodeId=c3131492856e8, content=<a href='/topic/show?id=447732948d0' target=_blank style='color:#2F92EE;'>#功能预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32948, encryptionId=447732948d0, topicName=功能预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=728c8977388, createdName=zsyan, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610030, encodeId=8dfe161003071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=813235, encodeId=5015813235f8, content=号好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61664774766, createdName=www.kangshiyizs, createdTime=Tue Aug 25 23:00:14 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006908, encodeId=dda9200690809, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat May 23 05:10:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492856, encodeId=c3131492856e8, content=<a href='/topic/show?id=447732948d0' target=_blank style='color:#2F92EE;'>#功能预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32948, encryptionId=447732948d0, topicName=功能预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=728c8977388, createdName=zsyan, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610030, encodeId=8dfe161003071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=813235, encodeId=5015813235f8, content=号好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61664774766, createdName=www.kangshiyizs, createdTime=Tue Aug 25 23:00:14 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006908, encodeId=dda9200690809, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat May 23 05:10:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492856, encodeId=c3131492856e8, content=<a href='/topic/show?id=447732948d0' target=_blank style='color:#2F92EE;'>#功能预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32948, encryptionId=447732948d0, topicName=功能预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=728c8977388, createdName=zsyan, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610030, encodeId=8dfe161003071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 16 09:10:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]

相关资讯

ERAS理念下高龄患者髋部骨折再发急性心肌梗死围术期处理1例

患者,女,87岁,因晨起时不慎摔倒致右侧股骨颈骨折(见图1)。既往2012年诊断脑梗塞,表现为嗜睡、左下肢无力,经药物治疗好转,无明显后遗症。2015年诊断急性前壁心梗,但未行支架置入再通术,药物(单硝酸异山梨酯、尼可地尔、螺内酯、托拉噻米、比索洛尔、氯吡格雷)保守治疗。近期心绞痛仍时有发作,心前区憋痛,无明显规律性,休息时亦可发生,含服硝酸甘油可缓解。

JACC:采用单次测量hs-cTnI的心肌梗死风险分层

目前,采用美国FDA批准的高灵敏度心肌肌钙蛋白I(hs-cTnI)测定进行快速风险分层的相关数据有限。Yader Sandoval等研究者发表在JACC的一项最新研究,旨在探讨单次测量hs-cTnI,以确定急性心肌梗死(AMI)低风险和高风险的患者。

Eur Heart J:急性心肌梗死出血事件的时间趋势

由此可见,在过去的20年中,开始有创治疗和更强烈的抗血栓治疗与出血事件的增加有关,但伴随着缺血事件的显著减少。

Clin Chem:高灵敏度心肌肌钙蛋白I可检测早期诊断急性心肌梗死

本研究的目的是验证Beckman Access高敏感性心肌肌钙蛋白I (hs-cTnI)检测的临床表现。研究人员收集急性心肌梗死(AMI)症状的急诊患者。由2名独立的心脏病专家进行集中判定诊断结果,所有临床信息包括心脏成像两次:第一次使用系列hs-cTnT (Elecsys, primary analysis),第二次使用hs-cTnI (Architect, secondary analys

隐匿性冠心病术中突发室颤并急性心肌梗死抢救成功一例

患者,男,58岁,53kg,诊断为“胆总管结石”,拟在全麻下行腹腔镜胆总管切开取石术。吸烟20余年,每天20支,已戒烟。既往糖尿病史10余年,血糖浓度控制在8~9mmol/L。否认高血压、冠心病等心血管疾病史。血常规提示轻度贫血,胸片、肝功能、凝血四项正常,ASA Ⅱ级,心肺听诊未闻及异常。

中国ACS患者血脂管理的现状与挑战

为进一步优化中国急性冠脉综合征(Acute coronary syndrome,ACS)患者全程管理,尤其是其长期血脂管理。2019欧洲心脏病学会(ESC)年会期间来自中国的三位心血管病学专家:北京大学第一医院霍勇教授、复旦大学中山医院葛均波院士以及中国人民解放军总医院陈韵岱教授与多位欧洲专家共同参与了“中欧ACS标准化管理学术交流启动会”。三位专家在会上也对中国ACS患者全程管理,尤其是血脂管理

Baidu
map
Baidu
map
Baidu
map